eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2021
vol. 17
 
Share:
Share:
more
 
 
abstract:
Original paper

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy

Michał Hawranek
1
,
Łukasz Pyka
1
,
Bożena Szyguła-Jurkiewicz
1
,
Piotr Desperak
1
,
Wioletta Szczurek
1
,
Andrzej Lekston
1
,
Michał Zembala
2
,
Szymon Pawlak
2
,
Mariusz Gąsior
1
,
Piotr Przybyłowski
2, 3

1.
3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
2.
Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
3.
First Department of General Surgery, Jagiellonian University, Medical College, Krakow, Poland
Adv Interv Cardiol 2021; 17, 4 (66): 349–355
Online publish date: 2021/12/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Cardiac allograft vasculopathy remains one of the most important factors leading to chronic cardiac allograft rejection. When revascularization is needed percutaneous coronary interventions are the method of choice.

Aim: To compare the short- and long-term outcomes of cardiac allograft vasculopathy patients treated with everolimus- (EES) or sirolimus-eluting stents (SES).

Material and methods
Between December 2012 and December 2020, 319 patients after heart transplantation undergoing coronary angiography at our institution were analysed. Subsequently 39 patients underwent de novo angioplasty with second-generation EES. The primary study endpoint was angiographic restenosis as evaluated by quantitative coronary angiography. Secondary outcomes included binary restenosis, target lesion revascularization and cardiac death during the follow-up period (6 months).

Results
Twenty-four patients were treated with EES and 15 treated with SES. No significant differences were observed regarding the rate of risk factors of cardiovascular diseases and comorbidities. The patients treated with EES were younger (55.8 ±11.8 vs. 60.1 ±12.2) and less frequently male (79% vs. 93%). The majority of patients were diagnosed with single vessel disease with LAD involvement (62% and 86% in the EES group, and 47% and 56% in the SES group). In 6 months follow-up, late lumen loss was comparable in both groups, 0.19 ±0.15 vs. 0.14 ±0.15, and binary restenosis was 4% and 0% for EES and SES groups, respectively.

Conclusions
Second generation drug-eluting stents eluting rapamycin analogues are associated with high direct efficacy of procedures and low incidence of restenosis in a 6-month follow-up.

keywords:

cardiac allograft vasculopathy, percutaneous coronary intervention, drug-eluting stents

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.